Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring

키워드

참고문헌 (13)

1. Tsai YN, "Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation", Clin Mol Hepatol, 30, pp.98~108 (2024)
2. Liaw YF, "Letter regarding : Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation", Clin Mol Hepatol, 30, pp.269~271 (2024)
3. Inoue T, "Hepatitis B core-related antigen : A novel and promising surrogate biomarker to guide antihepatitis B virus therapy", Clin Mol Hepatol, 29, pp.851~868 (2023)
4. Pazzagli L, "Methods for time-varying exposure related problems in pharmacoepidemiology : An overview", Pharmacoepidemiol Drug Saf, 27, pp.148~160 (2018)
5. Hsu YC, "Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk", Aliment Pharmacol Ther, 49, pp.107~115 (2019)
6. Hsu YC, "Association between serum level of hepatitis B surface antigen at end of entecavir therapy and risk of relapse in e antigen-negative patients", Clin Gastroenterol Hepatol, 14, pp.1490~1498 (2016)
7. Chen CH, "Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic hepatitis B virus infection", Clin Gastroenterol Hepatol, 13, pp.1984~1992 (2015)
8. Heinze G, "Variable selection-A review and recommendations for the practicing statistician", Biom J, 60, pp.431~449 (2018)
9. Tsai YN, "Letter : Estimating the incidence of HBsAg seroclearance after cessation of tenofovir and entecavir-potential influence of censored observation", Aliment Pharmacol Ther, 59, pp.136~137 (2024)
10. Kao JH, "APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients", Hepatol Int, 15, pp.833~851 (2021)
11. Hsu YC, "Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy", J Gastroenterol Hepatol, 32, pp.1512~1519 (2017)
12. Liu YC, "The role of offtherapy viral kinetics in the timing and severity of flares in hepatitis B e antigen-negative patients", Clin Gastroenterol Hepatol, 21, pp.1533~1541 (2023)
13. Su TH, "Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy", J Infect Dis, 217, pp.1193~1201 (2018)

관련 논문AI추천